Clinical Associate Professor Thomas Lee

• Inflammatory Bowel Disease

• Impact of iron therapy in gastrointestinal conditions

• Gut-brain axis in clinical practice

• Mesenteric fat and inflammation

• Thomas Lee, Thomas Clavel, Kirill Smirnov, Annemarie Schmidt, Ilias Lagkouvardos, Alesia Walter, Marinna Lucio, Philippe Schmitt-Kopplin, Richard Fedorak, Dirk Haller. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with inflammatory bowel diseases. Gut 2016;0-9.
• Candace Beilman, Nguyen Xuan Thanh, Victoria Ung, Christopher Ma, Karen Wong, Karen Kroeker, Thomas Lee, Haili Wang, Arto Ohinmaa, Philip D. Jacobs, Brendan Halloran and Richard Neil Fedorak. Real-Life Treatment Paradigms Show Adalimumab is Cost-Effective for the Management of Ulcerative Colitis. Canadian Journal of Gastroenterology and Hepatology 2016
• Chen JH, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TW, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-Smith G, Lawrance IC, McLachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Thomas W Lee MBBS MSc FRACP Jan 2018 Group.Review article: acute severe ulcerative colitis – evidence-based consensus statements. Aliment Pharmacol Ther. 2016 Jul;44(2):127-44.
• Ung V, Lee TW, Wang H, Kroeker KI, Nguyen TX, Ohinmaa A, Jacobs P, Wong K, Fedorak RN. Real-Life Treatment Paradigms Show Infliximab Is Cost-Effective For Management Of Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2014
• Lee TW, Russell L, Deng MG, Gibson PR. Association of doxycycline use with the development of acute and chronic Gastrointestinal illness in Australians deployed abroad. Internal Medicine Journal April 2013
• Lee T, Kolber M, Fedorak R and V van Zanten. Systematic review and meta-analysis: Comparing the efficacy of intravenous iron versus oral iron replacement therapy in iron deficient patients with IBD. J Crohns Colitis. 2012 Apr;6(3):267-75.
• Lee TW, Singh R, Fedorak RN. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. Aliment Pharmacol Ther. 2011; 34 (2):181-187.
• Lee TW, Fedorak RN. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am. 2010 Sep; 39 (3):543-57.
• Lee TW, Iser JH, Sparrow MP, Newnham ED, Headon BJ, Gibson PR. Thiopurines, a previously unrecognised cause for fatigue in patients with inflammatory bowel disease. J Crohns Colitis. 2009 Sep; 3 (3):196-9.

Past grants

2014

Evidence to Practice Grant (Cancer Institute NSW): Bowel preparation: An intervention targeting patient factors to improve the quality of bowel preparation to increase the efficiency of colonoscopy service after a positive faecal occult blood test

2013 -2014 

Ferming IBD Clinician Establishment Award (GESA): Awarded to an individual relativity early in their Gastroenterology career who has developed special skills in Inflammatory Bowell Disease (IBD) clinical management to enable the clinician to establish or become established in a specific IBD service within a hospital.

2012

IHMRI Pilot Grant: Exome (genotype) sequencing in Crohn’s disease: deciphering host genotype/microbial relationships, Caroline Kerr, Bianca Suesse, Thomas Lee, Paul Pavli.

• Clinical Associate Professor, School of Medicine, University of Wollongong